Prospective, Randomized, Multicenter, Open Label, Phase II Study to Access Efficacy and Safety of Lucentis® Monotherapy Compared With Lucentis® Plus Panretinal Photocoagulation (PRP) and PRP in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy

Inclusion Criteria: * High-risk proliferative diabetic retinopathy (HR-PDR) eyes. * Best Corrected-Visual Acuity at baseline \> 20/320 in the study eye. * Clear ocular media and adequate pupillary dilatation to permit good quality fundus photography. * Intraocular pressure \< 21 mmHg. * Type I, or Type II diabetic subjects as defined by the World Health Organization criteria of either gender, and aged ≥ 18 years. * Women must be using effective contraception, be post-menopausal for at least 12 months prior to trial entry, or surgically sterile. * Ability to provide written informed consent. * Ability to return for all trial visits. Exclusion Criteria: * Eyes with prior scatter (panretinal) or focal/grid photocoagulation, within the previous 6 months. * Fibrovascular proliferation with retinal traction. * Other cause of retinal neovascularization (retinal vein occlusion, radiation retinopathy or others). * Atrophy/scarring/fibrosis/ hard exudates involving the center of the macula. * Subjects who have received yttrium-aluminum-garnet laser, or peripheral retinal cryoablation, or laser retinopexy (for retinal tears only), or focal/grid photocoagulation, within the previous 6 months. * Significant media opacities, which might interfere with visual acuity, assessment of toxicity or fundus photography. * Subjects should not be entered if there is likelihood that they will require cataract surgery within the following 1 year. * Any intraocular surgery within 6 months before trial enrollment. * Previous vitrectomy. * HbA1C level \>11% or recent signs of uncontrolled diabetes. * Any of the following underlying systemic diseases: * History or evidence of severe cardiac disease. * History or evidence of clinically significant peripheral vascular disease such as intermittent claudication or prior amputation. * Clinically significant impaired renal function (serum creatinine \>2.5 mg/dL or s/p renal transplant or receiving dialysis). * Clinically significant impaired hepatic function. * Stroke (within 12 months of trial entry). * Any major surgical procedure within one month before trial enrollment. * Previous radiation to the head in the region of the study eye. * Any prior treatment with an investigational agent for diabetic retinopathy or anti-VEGF therapy (including intravitreal, subconjunctival or subtenons corticosteroids) during the past 90 days for any other condition. * Known serious allergies to fluorescein used in angiography, or to components of Lucentis® formulation. * Systolic Blood Pressure \> 170 (2 different readings) or diastolic Blood Pressure \> 100 (2 different readings). * Acute ocular or periocular infection. * Previous filtering surgery (e.g., trabeculectomy) or placement of a glaucoma drainage device (e.g., tube-shunt surgery). * Use of other investigational drugs at the time of enrollment. * History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes. * History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases. * Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (\> 5 mIU/mL). * Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant UNLESS they are: women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner; women whose partners have been sterilized by vasectomy or other means using a highly effective method of birth control. Periodic abstinence are not acceptable.